10-Q: Inhibrx Q2 2025: Reduced Burn, Key Trial Data Looms

Inhibrx Biosciences reports significantly reduced operating expenses and a new debt facility in Q2 2025, as it awaits crucial clinical trial data for its lead therapeutic candidates later this year.

Summary

• Reported a net loss of $28.654 million for the three months ended June 30, 2025, compared to a net income of $1,858.011 million in the prior-year period, which included a significant non-recurring gain from the Sanofi transaction.
• Operating expenses decreased substantially by $132.309 million (82%) to $28.689 million for Q2 2025, primarily due to the spin-off of the INBRX-101 program and reduced merger-related costs.
• Research and development (R&D) expenses fell by $45.365 million (67%) to $22.267 million in Q2 2025, driven by the INBRX-101 spin-off, decreased contract manufacturing, and lower personnel-related costs.
• General and administrative (G&A) expenses decreased by $86.944 million (93%) to $6.422 million in Q2 2025, mainly due to the absence of $67.5 million in merger-related expenses incurred in the prior year.
• Cash and cash equivalents increased to $186.567 million as of June 30, 2025, up from $152.596 million at December 31, 2024, largely due to proceeds from a new $100.0 million loan agreement.
• Accumulated deficit increased to $178.097 million as of June 30, 2025, from $106.132 million at December 31, 2024.
• The company initiated a new $100.0 million Loan and Security Agreement with Oxford in January 2025, with an option for an additional $50.0 million at Oxford's discretion.
• Key clinical trial data for ozekibart (INBRX-109) in chondrosarcoma, Ewing sarcoma, and colorectal adenocarcinoma are anticipated by late October 2025.
• A seamless Phase 2/3 clinical trial for INBRX-106 in combination with Keytruda for first-line HNSCC was initiated in June 2024, with initial Phase 2 data expected in Q4 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company continues to incur net losses from operations, the significant reduction in operating expenses post-spin-off demonstrates improved cost management. The new debt facility strengthens the cash position, and the pipeline is advancing with multiple key clinical data readouts expected in the near future, which are significant catalysts. However, the company remains a clinical-stage entity with a limited cash runway, necessitating future capital raises and carrying inherent risks associated with drug development.

Positives

• Significant reduction in operating expenses, including R&D and G&A, indicating improved cost control post-spin-off.
• Successful securing of a new $100.0 million loan facility, enhancing the company's cash position and extending its liquidity runway.
• Advancement of key clinical programs, with ozekibart (INBRX-109) Phase 2 trial in chondrosarcoma completing enrollment and interim data expected soon for multiple indications.
• Initiation of a seamless Phase 2/3 clinical trial for INBRX-106 in HNSCC, demonstrating progress towards potential registrational studies.
• Anticipated release of multiple clinical data readouts for ozekibart and INBRX-106 in late October and Q4 2025, which could be significant catalysts.

Negatives

• Reported a net loss of $28.654 million for Q2 2025 and $71.965 million for the six months ended June 30, 2025, indicating continued unprofitability from operations.
• Accumulated deficit increased to $178.097 million, reflecting ongoing losses from drug discovery and development activities.
• Reliance on future capital raises (equity offerings, debt financings, or collaborations) to fund operations beyond the next 12 months, which could lead to shareholder dilution.
• Interest expense of $3.141 million in Q2 2025 and $5.830 million for the six months ended June 30, 2025, due to the new loan agreement.

Risks

• Uncertainty regarding the timing, progress, results, and costs of research and development programs, preclinical studies, and clinical trials.
• Inability to successfully advance therapeutic candidates into, and complete, clinical trials.
• Potential for interpretations of initial, interim, or preliminary clinical data to be inaccurate or not indicative of final results.
• Uncertainty surrounding the timing or likelihood of regulatory filings and approvals for therapeutic candidates.
• Challenges in commercializing therapeutic candidates, if approved, including pricing, coverage, and reimbursement.
• Ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, and reliance on third-party suppliers and manufacturers.
• Ability to establish and maintain intellectual property rights covering therapeutic candidates.
• Ability to enter into strategic partnerships and the potential benefits of such partnerships.
• Future results of operations and financial position, and estimates regarding expenses, capital requirements, and needs for additional financing.
• Ability to raise funds needed to satisfy capital requirements, which may depend on financial, economic, and market conditions beyond control.
• Ability of third-party partners and service providers to continue operations and advance therapeutic candidates through clinical trials amidst market conditions, pandemics, regional conflicts, or natural disasters.
• Ability to retain key professionals and to identify, hire, and retain additional qualified professionals.
• Developments relating to competitors and the industry, which is highly competitive and rapidly changing.

Future Outlook

The company expects to continue incurring significant expenses and operating losses as it advances its therapeutic candidates through development and clinical trials, and seeks regulatory approval. Research and development expenses are anticipated to increase as candidates move into later-stage clinical development and pre-commercialization activities begin. The company believes its existing cash and cash equivalents are sufficient to fund operations for at least 12 months from the filing date, but plans to finance future cash needs through equity offerings, debt financings, or other capital sources like collaborations and strategic transactions. Key clinical data readouts for ozekibart are expected by late October 2025, and for INBRX-106 in Q4 2025, which could ungate a Phase 3 portion for the HNSCC program.

Management Comments

• We expect that research and development expense will continue to increase over the next several years as we continue development of our therapeutic candidates currently in clinical stage development and support our preclinical programs.
• We expect certain of our G&A expenses will continue to increase in the future to support our continued research and development activities, including costs related to pre-commercialization and business development activities.
• Based upon our current operating plans, we believe that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months from the date of filing of this Quarterly Report.

Industry Context

Inhibrx Biosciences operates as a clinical-stage biopharmaceutical company, a sector characterized by high research and development costs, significant capital requirements, and long development timelines. The company's focus on novel biologic therapeutic candidates, particularly in oncology, aligns with a growing trend in the biotech industry towards targeted therapies and protein engineering. The spin-off of its INBRX-101 program to Sanofi reflects a strategic move common in the industry to streamline focus on core pipeline assets and monetize mature programs, while also providing a significant capital infusion.

Comparison to Industry Standards

• The company's R&D expenditure, while significantly reduced post-spin-off, remains substantial, which is typical for clinical-stage biopharmaceutical companies advancing multiple programs like ozekibart and INBRX-106 through Phase 1/2 and Phase 2/3 trials.
• The cash burn from operating activities, though improved, is consistent with the high capital intensity required for drug development, particularly as programs approach later clinical stages and manufacturing scale-up.
• The securing of a new $100.0 million debt facility from Oxford Finance LLC is a common financing strategy for biotechs to extend their cash runway without immediate equity dilution, similar to facilities obtained by other clinical-stage companies to fund ongoing trials and operations.
• The company's liquidity runway of at least 12 months is a common benchmark for biotechs, indicating a need for future financing rounds, which is standard practice in the industry given the extensive costs of bringing a drug to market.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings. May be involved in legal proceedings or subject to claims incident to the ordinary course of business from time to time.

Related Party Transactions

• The Acquirer (Sanofi S.A.) is identified as a related party following the Merger with the Former Parent, retaining an 8% equity interest in the Company upon the Distribution.
• Entered into a Transition Services Agreement with the Former Parent (now a Sanofi entity) to provide certain transition services for a limited time, though no services were billed during the three and six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Potential for future dilution due to anticipated capital raises, but also potential for value creation from successful clinical trial outcomes.
• Employees: Decreased headcount in R&D and G&A functions, but new equity incentive plan in place for retention and motivation.
• Creditors: New debt facility provides capital, but also introduces new interest payment obligations and a secured lien on company assets.
• Customers (future): Progress in clinical trials brings therapeutic candidates closer to potential commercialization, offering future treatment options.

Next Steps

• Announce data from the registration-enabling Phase 2 trial for ozekibart (INBRX-109) in unresectable or metastatic conventional chondrosarcoma by late October 2025.
• Announce interim data on the Ewing sarcoma and colorectal adenocarcinoma cohorts of the Phase 1/2 trial evaluating ozekibart (INBRX-109) by late October 2025.
• Provide a more mature dataset update on INBRX-106 cohorts (NSCLC in combination with Keytruda and NSCLC with chemotherapy) during the fourth quarter of 2025.
• Announce initial Phase 2 data for INBRX-106 in combination with Keytruda as a first-line treatment for HNSCC during the fourth quarter of 2025.
• If Phase 2 data for INBRX-106 in HNSCC is positive, ungate the Phase 3 portion of the study, which is expected to enroll approximately 350 patients.

Key Dates

Recommendation

The company is in a transitional phase post-spin-off, with significantly reduced operating expenses and a strengthened cash position from new debt. However, it remains unprofitable from operations and will require additional capital within 12 months. The investment thesis heavily relies on the upcoming clinical trial data for ozekibart and INBRX-106 in late 2025. Until these crucial data readouts are available and their implications for regulatory pathways and commercial potential are clearer, a 'hold' recommendation is appropriate, as the stock's near-term movement will likely be driven by these binary clinical events.

Keywords

Biopharmaceutical, Clinical-stage, Oncology, DR5 agonist, OX40 agonist, Ozekibart, INBRX-106, Chondrosarcoma, Ewing sarcoma, Colorectal cancer, NSCLC, HNSCC, SEC filing, 10-Q, Biotech, Drug development, Clinical trials